Pharmacogenetics Update on Biologic Therapy in Psoriasis

• Published in: Medicina (Kaunas, Lithuania) Vol. 56; no. 12; p. 719
• Main Authors: Muñoz-Aceituno, Ester, Martos-Cabrera, Luisa, Ovejero-Benito, María Carmen, Reolid, Alejandra, Abad-Santos, Francisco, Daudén, Esteban
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 20-12-2020; MDPI AG
• Subjects: anti-IL12/23; anti-IL17; Biological Therapy; biologics; Genome-Wide Association Study; Humans; Pharmacogenetics; psoriasis; Psoriasis - drug therapy; Psoriasis - genetics; Review; Tumor Necrosis Factor-alpha - genetics; Pharmacogenetics; anti-IL12/23; biologics; psoriasis; anti-IL17
• DOI: 10.3390/medicina56120719
• EISSN: 1648-9144
• ISSN: 1648-9144; 1010-660X

Psoriasis is a chronic immune-mediated skin disease caused by several complex factors, both environmental and genetic, many of which are still not fully understood. Nowadays, several groups of biological drugs are being used for psoriasis treatment. Although these therapies are very effective, they show significant variability in efficacy among individuals. Therefore, there is a need for biomarkers to predict treatment outcomes in order to guide personalized therapeutic decisions. Pharmacogenetics is the study of variations in DNA sequences related to drug response.
In this article, we review pharmacogenetics studies on the treatment of moderate-to-severe psoriasis focusing on anti-interleukin (IL) 12/23 (ustekinumab) and anti-IL17 drugs (secukinumab and ixekizumab), as well as recent studies concerning anti-TNF drugs.
Several polymorphisms have been studied over the years in reference to anti-TNF drugs; some of the most recent studies included the performance of a genome-wide association study (GWAS) and pharmacogenetics studies focused on the optimization of a treatment regimen. Various polymorphisms in different genes have been related to ustekinumab response; among them, the most commonly studied is the HLA-C*06:02 allele.
Although not confirmed in some studies, most studies have shown that patients carrying this allele present a significantly higher response rate to ustekinumab. Some polymorphisms have been studied in patients treated with anti-IL17 drugs, mostly related to secukinumab; however, up to now, no association has been found between any of these polymorphisms and response. Nevertheless, further studies involving larger cohorts are needed in order to confirm these results before the implementation of this biomarker in clinical practice.